Bristol-Myers Squibb Procurement

Bristol Myers, schizophrenia

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the latter part of the year.

Hosted on MSN · 19h

Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts

Bristol Myers Squibb (BMY) ended the recent trading session at $56.29, demonstrating a -0.16% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1%.

Business Insider · 3d

Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older

Bloomberg on MSN · 4d

Bristol Myers Says New Schizophrenia Drug Off to Strong Start

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna Therapeutics is paying off.

Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Nasdaq7d

Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?

Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Hosted on MSN3d

Earnings Preview: What To Expect From Bristol-Myers Squibb's Report

Valued at a market cap of $113.1 billion, Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company ...

ArsenalBios Says Bristol Myers Squibb Exercises Exclusive License Option For AB-4000 Series Programs

Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...

Yahoo Finance27d

Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst institutional investors who own 78%

Every investor in Bristol-Myers Squibb Company (NYSE:BMY) should be aware of the most powerful shareholder groups. With 78% stake, institutions possess the maximum shares in the company.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results